Loading
Life sciences · Phase 4 Trial
ClinicalTrials.gov · October 27, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 4 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT04649229). This is a study registration, not published results. Lead sponsor: Yale University. Recruitment status: COMPLETED. Phase: PHASE4. Study type: INTERVENTIONAL. Enrollment: 46 participants (ACTUAL). Conditions: Heart Failure. Interventions: DRUG: LCZ 696; DRUG: Placebo; DRUG: Para-aminohippurate; DRUG: Iohexol; DRUG: Aprepitant. Primary outcome measures: Max Change in Mean Arterial Pressure (MAP) , The maximal change in MAP, as measured by the lowest MAP recorded six hours following drug administration minus the baseline MAP.; Urine Sodium Excretion , Total urine output from drug administration to six hours following drug administration. Brief summary: This is a double-blind, randomized, two x two crossover (aprepitant vs placebo) during both initiation of Entresto, LCZ696, (50 mg dose) and at steady-state of Entresto (200 mg bid dose or the highest tolerated dose).